All articles

NeoSci Ventures Raises $53M First Close for Debut Biotech Fund

Date
Read9 min read
NeoSci Ventures Raises $53M First Close for Debut Biotech Fund

TL;DR

NeoSci Ventures, the Singapore-based biotech investment firm known as NSV, has pulled in a S$70 million (roughly US$53-55 million, depending on the exchange rate used) first close for its first institutional venture fund. The vehicle has no publicly disclosed name or final target, but it already carries a notable LP roster for a debut fund: Taiwan's National Development Fund, Singapore state investor EDBI, Taiwanese manufacturer Catcher Technology, and property-and-investment group Crescendas, alongside unnamed family offices and entrepreneurs. NSV isn't a new name in Asian biotech even though this is its first outside-capital fund: the team has spent years co-founding and building therapeutics companies in-house, including Enleofen Bio (acquired by Boehringer Ingelheim) and Tango Therapeutics (now Nasdaq-listed), through its NSG BioLabs lab-and-incubator arm. The new fund has already put money into two companies, one of them named (Protuoso Bio, an NSV-founded company) and one not. It matters because it's a rare debut fund in biotech venture that opens with government-linked, strategic-corporate LPs rather than a slow build from family-office money, and because it formalizes a venture-creation model that Asian biotech has mostly imported from Boston and Cambridge.

Key Takeaways

A venture builder just became a fund manager. NSV spent years building biotech companies from scratch inside NSG BioLabs before raising a dollar of institutional capital. The first close of its inaugural fund turns that track record into a repeatable, LP-backed vehicle rather than a one-off platform play, which is a meaningfully different business than running an incubator.

The LP list reads like a biotech industrial policy wish list. Taiwan's National Development Fund and Catcher Technology (a major Apple and electronics supplier) sitting alongside Singapore's EDBI points to two governments and at least one large manufacturer treating biotech venture capital as strategic infrastructure, not just a financial allocation.

The fund is already deployed, not just raised. Two investments are already out of this vehicle, including Protuoso Bio. A fund that's writing checks before it finishes fundraising is a signal GPs want you to notice: pipeline visibility and conviction, not a cold start.

US-Asia biotech arbitrage is the explicit thesis. NSV is positioning itself to move therapeutic assets and platform technology between Asia's drug-development pipeline and US capital markets and acquirers, which is exactly the trade that made Enleofen and Tango work for the team previously.

Fund Overview

Fund Name: Not publicly disclosed; referred to in press coverage as NSV's inaugural institutional venture fund
Fund Size: S$70 million first close (reported as approximately US$53 million to US$55 million depending on the conversion rate cited; no target or final close size has been disclosed)
Stage: Early-stage biotech venture creation and investment
Check Size: Not disclosed
Geography: United States and Asia, with offices in Singapore, Taiwan and the US
Focus: Biotechnology and healthcare companies developing new therapeutics and technologies, including work at the intersection of biology, AI, data and scientific tools
Key LPs: Taiwan's National Development Fund, Singapore's EDBI, Catcher Technology, Crescendas Group, plus undisclosed family offices and entrepreneurs

Why This Fund Matters

Most debut biotech funds spend their first few years proving they can pick winners before anyone with a government mandate writes them a check. NSV skipped that step by doing the picking first, outside a formal fund structure. For years the team has operated as a venture builder through NSG BioLabs, a Singapore lab-and-office facility that has hosted dozens of biotech companies, and NSV itself has co-founded therapeutics companies rather than just investing in them after the fact. Enleofen Bio, sold to Boehringer Ingelheim, and Tango Therapeutics, now trading on the Nasdaq, are the two proof points the firm can point to. That's a different credibility problem than a typical debut fund has to solve, and it likely explains why the first close attracted sovereign and strategic capital rather than the friends-and-family round most first-time managers start with.

The LP list is the real story here. Taiwan's National Development Fund and Singapore's EDBI are both policy-adjacent vehicles that use venture capital allocations to build domestic biotech and life-sciences capacity, and Catcher Technology, a Taiwanese manufacturer best known for supplying Apple, is a strategic corporate LP rather than a financial one. Putting those three in the same cap table as a debut fund signals that at least two governments see Asia-to-global biotech venture creation as worth underwriting directly, not just as a sector to regulate.

Geographically, NSV is explicit about wanting to move in both directions: sourcing therapeutic assets and platform science out of Asia's drug-development base, and connecting them to US capital markets, acquirers and talent. That's the exact trade that worked with Enleofen and Tango, and it's a thesis that only a handful of firms are built to execute credibly, since it requires real operating relationships on both sides of the Pacific rather than just a thesis slide.

The fund is also notable for what it's already done rather than what it says it will do. Two investments are already out the door, with Protuoso Bio named publicly and a second undisclosed. For LPs evaluating a debut vehicle, a fund that's already deploying with conviction is a different risk profile than one that's still building its pipeline from zero.

The Team

NSV's leadership is built around two founding partners with complementary backgrounds. Daphne Teo, founding partner, is also the founder and CEO of NeoSci Ventures and of NSG BioLabs, the lab-and-incubator platform that underpins NSV's venture-building track record. Timothy Lu, also a founding partner, serves as the firm's managing director; press coverage of the fund close referred to him as founding chief scientist, reflecting his role spanning both the scientific and operating sides of the firm's portfolio companies. The firm's own team page also lists a third founding partner, Jeffrey Lu, who was not named in any of the press coverage of this fund close; readers should treat his specific role on the new fund as unconfirmed until NSV says more. Beyond the three founding partners, NSV's site lists a CFO (Darin Baur), two venture partners, and a small investment and operations team, which is a lean structure for a firm managing an active portfolio alongside a new institutional fund.

Early Portfolio

The new fund has deployed into two companies so far. The one NSV has named publicly is Protuoso Bio, a company NSV co-founded, consistent with the firm's venture-building approach. The second investment has not been disclosed. Outside the new fund, NSV and NSG BioLabs' broader track record includes Enleofen Bio (acquired by Boehringer Ingelheim), Tango Therapeutics (now Nasdaq-listed), and other companies that have gone public or been acquired; press accounts differ slightly on exactly how many biotech companies have passed through NSG BioLabs over the years, so we're not repeating a specific count here.

What This Means for Founders

Therapeutics and platform-technology founders working across Asia and the US, especially those whose science sits at the intersection of biology, AI and data, are the clearest fit for NSV's thesis. Because the firm's roots are in venture building rather than pure check-writing, founders working with NSV should expect a firm that wants real involvement in company formation and operations, not just a board seat and a wire transfer; that's a trade-off some founders will want and others won't.

The firm's LP base is also worth noting for founders thinking about downstream relationships. A cap table that already includes Taiwan's National Development Fund, Singapore's EDBI, and a strategic manufacturer like Catcher Technology can open doors into government procurement, manufacturing partnerships, and follow-on capital in both Taiwan and Singapore that a purely financial LP base wouldn't.

Fund Momentum Take

The interesting bet here isn't really "can NSV pick good biotech companies" — Enleofen and Tango already answered that. It's whether a venture-building shop can scale into a repeatable, LP-backed fund manager without diluting the hands-on, co-founder-level involvement that made its earlier deals work. Venture-building models are notoriously hard to scale precisely because they depend on a small number of people doing an unusually deep amount of operating work per company; raising outside capital adds reporting, governance and diversification pressure that can pull a firm away from exactly the behavior that built its track record.

The undisclosed second investment and the unnamed fund itself are worth watching rather than worrying about at this stage — funds frequently keep names and some holdings under wraps through a first close, and that's a normal publishing lag rather than a red flag. What we'd want to see before the final close is more clarity on check sizes and how much of the fund is earmarked for building new companies from scratch versus investing in outside deal flow, since those are different risk profiles for the same LP dollar.

Our read: this is a strong debut fund precisely because it isn't really a debut in the way the capital markets define one. The LPs clearly priced in a decade of venture-building history rather than underwriting a blank sheet, and that's a more defensible position than most first-time managers get to start from.

Frequently Asked Questions

What is NeoSci Ventures (NSV)?
NSV is a Singapore-based biotech venture firm with offices in Singapore, Taiwan and the US. It has operated for years as a venture builder through its NSG BioLabs lab-and-incubator platform, co-founding therapeutics companies, and has now raised its first institutional venture fund with outside LPs.

How much did NSV raise in this first close?
S$70 million, reported as roughly US$53 million to US$55 million depending on the exchange rate used. No fund name, target size, or expected final close amount has been publicly disclosed.

Who are NSV's limited partners?
Named LPs include Taiwan's National Development Fund, Singapore's EDBI, Taiwanese manufacturer Catcher Technology, and Crescendas Group, along with unnamed family offices and entrepreneurs.

What has NSV invested in so far?
The new fund has deployed into two companies: Protuoso Bio, which NSV co-founded, and a second, undisclosed company. Separately from the new fund, NSV's venture-building track record includes Enleofen Bio (acquired by Boehringer Ingelheim) and Tango Therapeutics (Nasdaq-listed).

Is NSV a traditional check-writing VC fund?
Not entirely. NSV blends in-house company creation through NSG BioLabs with outside investing, which is a model more common among a handful of specialist biotech venture builders than among generalist early-stage funds.


Have a fund closing to announce? Submit your fund here.

Need help raising capital? Check out our Fundraising Advisory services.

Related funds in the index

Biotech funds from the verified index

FundSizeStageLocationFocus
Sofinnova Crossover Fund II€725 million EURSeries CFranceBiotech, MedTech +1
LEA VenturesAround EUR 70M per fund, investing since 2017 EURPre SeedGermanyDeep Tech, Robotics & Automation +4
Noctua Science Ventures€15M EURPre SeedAustriaDeep Tech, SaaS +5
NeoSci Ventures (NSV) Fund IS$70M SGDSeedSingaporeBiotech, Digital Health +3
Genesys University Seed FundC$30M CADSeedCanadaBiotech, MedTech
Search all 950+ VC funds
Share
Connect your agent Free to start. No key, no signup.